Drug Type Recombinant protein, Prophylactic vaccine |
Synonyms- |
Target- |
Mechanism Influenza virus fusion inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Osivax SASStartup |
Active Organization Osivax SASStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Preclinical | FR | Osivax SASStartup | 12 Apr 2024 |